Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorWilliams Cancer Foundation
About this trial
SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Eligibility criteria
Qualifiers
Male or female, aged >18 years old at the time of signed informed consent
Provide written informed consent and must be willing to adhere with treatment and follow-up.
Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor who have not responded or progressed after standard therapies or for whom no further standard therapy exists or standard therapy is not available.
Meet all eligibility criteria
Disqualifiers
Has a known additional malignancy that is progressing or has required active treatment in the last 3 years, excluding basal and squamous cell carcinoma
Has undergone major surgery within 28 days prior to enrollment and has not recovered adequately from the toxicities and/or complications
Has an active infection (including tuberculosis) requiring systemic therapy
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
Trial design
Treatments tested in this trial
- SV-101
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Williams Cancer Foundation
Lead sponsor
Syncromune, Inc.
Collaborator
Source ClinicalTrials.gov